Appenzeller Paula, Lichtblau Mona, Berlier Charlotte, Aubert John-David, Azzola Andrea, Fellrath Jean-Marc, Geiser Thomas, Lador Frederic, Pohle Susanne, Opitz Isabelle, Schwerzmann Markus, Stricker Hans, Tamm Michael, Saxer Stéphanie, Ulrich Silvia
Clinic of Pulmonology, University Hospital Zurich Zurich Switzerland.
Center of Pulmonology, CHUV Lausanne Switzerland.
Pulm Circ. 2022 Jan 5;12(1):e12001. doi: 10.1002/pul2.12001. eCollection 2022 Jan.
Pulmonary hypertension (PH), especially pulmonary arterial and chronic thromboembolic pulmonary hypertension (PAH/CTEPH), are rare and progressive conditions. Despite recent advances in treatment and prognosis, PH is still associated with impaired quality of life and survival. Long-term PH-registry data provide information on the changing PH-epidemiology and may help to direct resources to patient's needs. This retrospective analysis of the Swiss Pulmonary Hypertension Registry includes patients newly diagnosed with PH (mainly PAH/CTEPH) registered from January 2001 to June 2019 at 13 Swiss hospitals. Patient characteristics (age, body mass index, gender, diagnosis), hemodynamics at baseline, treatment, days of follow-up, and events (death, transplantation, pulmonary endarterectomy, or loss to follow-up) at last visit were analyzed. Patients were stratified into four time periods according to their date of diagnosis. Survival was analyzed overall and separately for PAH/CTEPH and time periods. 1427 PH patients were included (thereof 560 PAH, 383 CTEPH). Over the years, age at baseline (mean ± SD) significantly increased from 59 ± 14 years in 2001-2005 to 66 ± 14 years in 2016-2019 ( < 0.001) while the gender distribution tended toward equality. Mean pulmonary artery pressure and pulmonary vascular resistance significantly decreased over time (from 46 ± 15 to 41 ± 11 mmHg, respectively, 9 ± 5 to 7 ± 4 WU, < 0.001). Three-year survival substantially increased over consecutive periods from 69% to 91% (for PAH 63%-95%, for CTEPH 86%-93%) and was poorer in PAH than CTEPH independently of time period ( < 0.001). Most patients were treated with mono- or combination therapy and an increasing number of CTEPH underwent pulmonary endarterectomy (40% 2016-2019 vs. 15% 2001-2005). This long-term PH registry reveals that over two decades of observation, newly diagnosed patients are older, less predominantly female, have less impaired hemodynamics and a better survival.
肺动脉高压(PH),尤其是肺动脉高压和慢性血栓栓塞性肺动脉高压(PAH/CTEPH),是罕见的进行性疾病。尽管在治疗和预后方面取得了最新进展,但PH仍与生活质量受损和生存率降低有关。长期的PH注册数据提供了有关PH流行病学变化的信息,并可能有助于根据患者需求分配资源。这项对瑞士肺动脉高压注册中心的回顾性分析纳入了2001年1月至2019年6月在瑞士13家医院新诊断为PH(主要是PAH/CTEPH)的患者。分析了患者特征(年龄、体重指数、性别、诊断)、基线血流动力学、治疗、随访天数以及最后一次就诊时的事件(死亡、移植、肺动脉内膜剥脱术或失访)。根据诊断日期将患者分为四个时间段。对总体生存率以及PAH/CTEPH和时间段分别进行了分析。共纳入1427例PH患者(其中560例PAH,383例CTEPH)。多年来,基线年龄(均值±标准差)从2001 - 2005年的59±14岁显著增加到2016 - 2019年的66±14岁(P<0.001),而性别分布趋于平等。平均肺动脉压和肺血管阻力随时间显著降低(分别从46±15降至41±11 mmHg,从9±5降至7±4 WU,P<0.001)。连续几个时间段的三年生存率从69%大幅提高到91%(PAH为63% - 95%,CTEPH为86% - 93%),且无论时间段如何,PAH的生存率均低于CTEPH(P<0.001)。大多数患者接受了单药或联合治疗,接受肺动脉内膜剥脱术的CTEPH患者数量不断增加(2016 - 2019年为40%,2001 - 2005年为15%)。这项长期的PH注册研究表明,经过二十多年的观察,新诊断的患者年龄更大,女性占比降低,血流动力学受损程度减轻,生存率更高。